MedTrace Logo

Anesthetic Effect of Ropivacaine on Local Infiltration Anesthesia in Arteriovenous Fistula Surgery

NCT07259772 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-09

No results posted yet for this study

Summary

This study compares two local anesthetics, ropivacaine and lidocaine, for patients undergoing arteriovenous fistula surgery. Arteriovenous fistula is the preferred vascular access for end-stage kidney disease patients needing hemodialysis.

In this clinical trial, patients are randomly assigned to receive either ropivacaine or lidocaine for local anesthesia during the surgery. Researchers are evaluating which medication provides better pain control and improves surgical outcomes.

The study is examining:

* Pain levels during and after surgery
* Surgery duration
* Need for additional pain medication
* Surgical complications
* Fistula development over time
* Long-term fistula function at 1 year and 5 years

This is a double-blind study, meaning neither patients nor surgeons know which medication is being used. The study is currently ongoing with active patient follow-up and is expected to be completed in June 2026. Patients are being followed for up to 5 years to monitor their long-term progress.

This research may help doctors choose the best local anesthetic for arteriovenous fistula surgery, potentially leading to better pain control and improved long-term outcomes for kidney disease patients.

Conditions

  • End Stage Renal Disease (ESRD)
  • Arteriovenous Fistula Patency
  • Chronic Kidney Disease 5D

Interventions

DRUG

Ropivacaine

0.375% ropivacaine solution (75 mg total dose in 20 mL volume) administered as local infiltration anesthesia for arteriovenous fistula surgery

DRUG

Lidocaine

0.67% lidocaine solution (100 mg total dose in 15 mL volume) administered as local infiltration anesthesia

Sponsors & Collaborators

  • The First People's Hospital of Lianyungang

    lead OTHER

Principal Investigators

  • Liyuan Zhang · Lianyungang First People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2021-03-31
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07259772 on ClinicalTrials.gov